Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JIGNESH P SHAH

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1063550291
CMS profile
320822
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$4,722.16

124 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,785.00 2
Food and Beverage $1,930.55 121
Education $6.61 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JIGNESH P SHAH

NPI 1063550291 · CMS profile ID 320822

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063550291?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JIGNESH P SHAH, NPI 1063550291, CMS profile ID 320822. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063550291?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JIGNESH P SHAH, NPI 1063550291, CMS profile ID 320822. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063550291?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JIGNESH P SHAH, NPI 1063550291, CMS profile ID 320822, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1063550291?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

124 matching records · $4,722.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 124 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 124.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $27.5906/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011385 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.6306/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849943841 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $0.8106/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850231715 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.1406/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820236525 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.3306/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820236519 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.4506/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850057835 CMS
Ironwood Pharmaceuticals, Inc $17.4405/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855104037 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.4605/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850184387 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.8905/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850320039 CMS
Merck Sharp & Dohme Corporation $15.7405/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848495765 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.1305/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820236513 CMS
AbbVie Inc. $24.8205/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011383 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.0205/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820236507 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.4305/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850266403 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.0705/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820236501 CMS
Braintree Laboratories, Inc. $18.3405/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805260829 CMS
AbbVie Inc. $22.1905/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011381 CMS
AbbVie Inc. $11.3104/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011379 CMS
Ironwood Pharmaceuticals, Inc $19.7904/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855125833 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $10.0004/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850115297 CMS
AbbVie Inc. $16.9204/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011377 CMS
Janssen Biotech, Inc. $18.5904/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788987993 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.8504/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820236495 CMS
AbbVie Inc. $19.0404/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011375 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,120.0004/20/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850053099 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.4604/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850349377 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.2404/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850403697 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.5704/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820236483 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3.1304/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820236489 CMS
AbbVie Inc. $25.5204/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011373 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.9604/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850193955 CMS
Takeda Pharmaceuticals U.S.A., Inc. $33.6404/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820236477 CMS
AbbVie Inc. $11.5504/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011371 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.1104/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849995273 CMS
AbbVie Inc. $10.4204/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011369 CMS
RedHill Biopharma Inc. $16.0604/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799944651 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.5304/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820236471 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.0803/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820236465 CMS
RedHill Biopharma Inc. $17.7403/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799944649 CMS
AbbVie Inc. $25.1803/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011367 CMS
Janssen Biotech, Inc. $15.2203/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788987991 CMS
AbbVie Inc. $28.2303/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011365 CMS
AbbVie Inc. $23.0003/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796011363 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.0403/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850137915 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.2203/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850144477 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.5403/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850339141 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.0903/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850405473 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $9.4203/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850423063 CMS
Ironwood Pharmaceuticals, Inc $19.4703/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855131793 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $6.6103/09/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850258471 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,958.67 44
PY2020 $1,103.26 45
PY2021 $4,722.16 124
PY2022 $2,679.53 79
PY2023 $10,333.23 85
PY2024 $33,489.59 110
PY2025 $73,323.37 195

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $278,918.30 52
PY2024 Principal investigator $907,836.79 125
PY2023 Recipient $2,287.54 3
PY2023 Principal investigator $89,029.09 13
PY2022 Principal investigator $168,853.78 23
PY2021 Recipient $24,012.60 1
PY2021 Principal investigator $15,302.20 2
PY2020 Recipient $1,342.50 3
PY2020 Principal investigator $71,923.41 6
PY2019 Principal investigator $51,556.53 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $11,694.00 12/04/2025 Non-covered Recipient Entity
Linq Research Llc
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226108873
Principal investigator 1 PFIZER INC. $4,514.00 10/20/2025 Non-covered Recipient Entity
Linq Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228739459
Principal investigator 1 SANOFI US SERVICES INC. $3,523.00 10/17/2025 Non-covered Recipient Entity
Linq Research Llc
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226108849
Principal investigator 1 ABBVIE INC. $2,682.45 10/09/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202515949
Principal investigator 1 Bausch Health US, LLC $175.00 09/24/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842436
Principal investigator 1 Bausch Health US, LLC $1,399.68 09/11/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842440
Principal investigator 1 SANOFI US SERVICES INC. $10,202.00 09/05/2025 Non-covered Recipient Entity
Linq Research Llc
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226108842
Principal investigator 1 ABBVIE INC. $7,264.35 09/04/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202509280
Principal investigator 1 ABBVIE INC. $9,175.95 08/26/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202505873
Principal investigator 1 ABBVIE INC. $255.00 08/14/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202504941
Principal investigator 1 ABBVIE INC. $9,175.95 08/14/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202504943
Principal investigator 1 Bausch Health US, LLC $1,399.68 08/08/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842431
Principal investigator 1 SANOFI US SERVICES INC. $3,086.00 08/08/2025 Non-covered Recipient Entity
Linq Research Llc
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226108819
Principal investigator 1 SANOFI US SERVICES INC. $100.00 08/08/2025 Non-covered Recipient Entity
Linq Research Llc
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226108827
Principal investigator 1 ABBVIE INC. $2,767.50 08/06/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202503581
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $28,316.00 07/29/2025 Covered Recipient Physician A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) No dispute reported 06/30/2026 1244051949
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7.70 07/29/2025 Covered Recipient Physician A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) No dispute reported 06/30/2026 1244051951
Principal investigator 1 Bausch Health US, LLC $1,619.59 07/09/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842444
Principal investigator 1 PFIZER INC. $1,001.00 07/02/2025 Non-covered Recipient Entity
Linq Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228755768
Principal investigator 1 PFIZER INC. $73.00 07/02/2025 Non-covered Recipient Entity
Linq Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228756939
Principal investigator 1 SANOFI US SERVICES INC. $33,553.00 07/02/2025 Non-covered Recipient Entity
Linq Research Llc
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226108814
Principal investigator 1 PFIZER INC. $113.74 06/20/2025 Non-covered Recipient Entity
Linq Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228790211
Principal investigator 1 PFIZER INC. $44.96 06/20/2025 Non-covered Recipient Entity
Linq Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228790291
Principal investigator 1 PFIZER INC. $1,800.00 06/20/2025 Non-covered Recipient Entity
Linq Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228790633
Principal investigator 1 PFIZER INC. $3,000.00 06/20/2025 Non-covered Recipient Entity
Linq Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228790873
Principal investigator 1 PFIZER INC. $2,850.00 06/20/2025 Non-covered Recipient Entity
Linq Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228792419
Principal investigator 1 PFIZER INC. $1,200.00 06/20/2025 Non-covered Recipient Entity
Linq Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228792832
Principal investigator 1 PFIZER INC. $3,500.00 06/20/2025 Non-covered Recipient Entity
Linq Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228793281
Principal investigator 1 PFIZER INC. $820.00 06/20/2025 Non-covered Recipient Entity
Linq Research LLC
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228793715
Principal investigator 1 ABBVIE INC. $7,650.00 06/12/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202491069
Principal investigator 1 Bausch Health US, LLC $1,675.49 06/11/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842471
Principal investigator 1 Bausch Health US, LLC $3,019.27 06/05/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842477
Principal investigator 1 ABBVIE INC. $3,226.50 06/03/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202487621
Principal investigator 1 ABBVIE INC. $9,175.95 05/22/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202485837
Principal investigator 1 Eli Lilly and Company $469.20 05/21/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB No dispute reported 06/30/2026 1187886354
Principal investigator 1 Bausch Health US, LLC $3,556.31 05/13/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842487
Principal investigator 1 ABBVIE INC. $425.00 05/08/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202484397
Principal investigator 1 ABBVIE INC. $2,767.50 05/07/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202483149
Principal investigator 1 ABBVIE INC. $19,000.00 05/07/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202483151
Principal investigator 1 Bausch Health US, LLC $3,019.27 05/07/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842481
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $69.30 05/06/2025 Non-covered Recipient Entity
Linq Research, LLC
A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) No dispute reported 06/30/2026 1244042079
Principal investigator 1 ABBVIE INC. $5,000.00 05/01/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202480781
Principal investigator 1 ABBVIE INC. $9,175.95 04/10/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202475806
Principal investigator 1 Bausch Health US, LLC $3,234.32 04/07/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842466
Principal investigator 1 ABBVIE INC. $2,848.50 04/03/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202471376
Principal investigator 1 Bausch Health US, LLC $3,776.22 04/01/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842484
Principal investigator 1 Bausch Health US, LLC $6,846.53 03/11/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842453
Principal investigator 1 ABBVIE INC. $10,327.50 03/07/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202461199
Principal investigator 1 Bausch Health US, LLC $962.28 03/05/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842462
Principal investigator 1 SANOFI US SERVICES INC. $29,419.00 03/04/2025 Non-covered Recipient Entity
Linq Research Llc
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226108808
Principal investigator 1 Bausch Health US, LLC $3,287.78 01/28/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842448
Principal investigator 1 Bausch Health US, LLC $4,672.88 01/07/2025 Non-covered Recipient Entity
LINQ Research LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842459

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $5,567.46 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $5,567.46 1
PY2022 Amount invested $349.70 1
PY2022 Value of interest $349.70 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

3 records · PY2022–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 GastroGPO, LLC $0.00 $5,567.46 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124820321
PY2023 GastroGPO, LLC $0.00 $5,567.46 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1050730651
PY2022 GastroGPO, LLC $349.70 $349.70 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 955001165